Status:
UNKNOWN
Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19
Lead Sponsor:
Corat Therapeutics Gmbh
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Primary objectives Part 1: \- To evaluate the safety and tolerability of COR-101 compared to placebo Secondary objectives Part 1: * To evaluate the preliminary efficacy of COR-101 compared to place...
Eligibility Criteria
Inclusion
- Key
- Hospitalized for COVID-19 illness for ≤72 hours
- Positive SARS-CoV-2 test by standard RT-PCR assay or equivalent test
- Presence of moderate to severe clinical signs indicative of moderate or severe illness with COVID19 prior to study treatment
- Key
Exclusion
- Diagnosis of asymptomatic COVID-19, mild COVID-19, or critical COVID-19
- In the opinion of the investigator, is not likely to survive for \>48 hours beyond Day 1
- New onset stroke or seizure disorder during hospitalization and prior to Day 1
- History of relevant CNS pathology or current relevant CNS pathology
Key Trial Info
Start Date :
April 21 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2022
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04674566
Start Date
April 21 2021
End Date
October 30 2022
Last Update
May 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Tübingen
Tübingen, Germany